STOCK TITAN

If You Invested in Drugs Made In America Acquisition Corp. Rights (DMAAR)

Blank Checks · NASDAQ
Looking for the current price? See the DMAAR quote & overview
$1,000 invested 1 Year Ago
$558
-44.2% price return -44.3% CAGR
-44.2% with dividends reinvested
Bought on Nov 5, 2025 at $0.1974 split-adjusted
$1,000 invested 5 Years Ago
N/A
Our prices start Feb 25, 2025
$1,000 invested 10 Years Ago
N/A
Our prices start Feb 25, 2025

What $1,000 or $10,000 in DMAAR Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Feb 25, 2025
$1,000 $558 -44% — — $729 -27%
$10,000 $5,578 -44% — — $7,291 -27%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-04. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for DMAAR

$1,000 Investment Over Time

DMAAR vs S&P 500

Year-by-Year Returns

DMAAR annual performance
Year Start Price End Price Annual Return Cumulative
2025Feb 25, 2025 to Dec 31, 2025 $0.1510 $0.1873 +24.0% +24.0%
2026Dec 31, 2025 to Nov 4, 2026 $0.1873 $0.1101 -41.2% -27.1%

About Drugs Made In America Acquisition Corp. Rights

NASDAQ

Current Price
$0.1101
View full DMAAR overview

Frequently Asked Questions

Drugs Made In America Acquisition Corp. Rights investment returns

How much would $1,000 invested in Drugs Made In America Acquisition Corp. Rights be worth today?

If you invested $1,000 in Drugs Made In America Acquisition Corp. Rights (DMAAR) 1 year ago on 2025-11-05, your investment would be worth $558 as of 2026-11-04, a -44.2% price return without dividends, growing at a compounded rate of -44.3% per year (CAGR).

Has Drugs Made In America Acquisition Corp. Rights outperformed the S&P 500?

Comparison data requires at least 10 years of trading history. Use the calculator above to compare DMAAR performance over available time periods.

For informational and educational purposes only, not investment advice.